Elysium, founded by Leonard Guarente, is on a mission is to translate critical scientific advancements in aging research into accessible health products and technologies. The current pipeline includes preclinical and clinical trials for skin, microbiome, muscle, cognition, UV damage, menopausal syndromes, and circadian rhythm. At present Elysium markets four products: Basis, Matter, Format, Signal, and Index. Although these products are categorized as supplements rather than pharmaceuticals, Elysium is setting up clinical trials to establish thieir safety and effectiveness. As of May 2023 Elysium has 18 clinical trials listed on clinicaltrials.gov. This foundation allows Elysium to establish an approach to scientific discovery and customer support that enables the pursuit of lifelong health and wellness. Basis is comprised ot two ingredients: Nicotinamide Riboside (NR) and Pterostilbene (PT), NR which is a naturally occurring form of vitamin B3 and a highly efficient precursor to NAD+, This is the raw material that the body uses to make NAD+ via a two-step process. Elysiums research indicates that their product preferentially elevates NAD+ compared to nicotinic acid and nicotinamide, also called niacin. Pterostilbene (PT) is a polyphenol naturally produced by plants to protect against internal and external stress. The combination of NR and pterostilbene in Basis is designed to increase NAD+ levels and counter the decrease in the activity of sirtuins, which occurs with normal aging.